Logo
x

Search

Subscribe Now

Otsuka

Otsuka and Lundbeck Receive the EC’s Approval for Rxulti to Treat Schizophrenia in Adolescents

Otsuka and Lundbeck Receive the EC’s Approval for Rxulti to Treat Schizophrenia in Adolescents

  • March 13, 2025
Otsuka and Astex Receive EC’s Approval for Inaqovi (decitabine and cedazuridine) to Treat Newly Diagnosed Acute Myeloid Leukaemia

Otsuka and Astex Receive EC’s Approval for Inaqovi (decitabine and cedazuridine) to Treat Newly Diagnosed Acute Myeloid Leukaemia

  • September 19, 2023
Otsuka Entered into a Multi-Target Collaboration with ShapeTX to Develop Novel AAV Gene Therapies for Ocular Diseases

Otsuka Entered into a Multi-Target Collaboration with ShapeTX to Develop Novel AAV Gene Therapies for Ocular Diseases

  • September 8, 2023
Otsuka and Lundbeck Receive the US FDA’s Approval for Rexulti (brexpiprazole) sNDA to Treat Agitation Associated with Dementia Due to Alzheimer’s Disease

Otsuka and Lundbeck Receive the US FDA’s Approval for Rexulti (brexpiprazole) sNDA to Treat Agitation Associated with Dementia Due...

  • May 12, 2023
Otsuka’s Lupkynis (voclosporin) Receives NICE Recommendation for the Treatment of Active Lupus Nephritis

Otsuka’s Lupkynis (voclosporin) Receives NICE Recommendation for the Treatment of Active Lupus Nephritis

  • May 4, 2023
Otsuka and Lundbeck’s Abilify Asimtufii (aripiprazole) Receive the US FDA’s Approval as First Long-Acting Injectable for Schizophrenia or Bipolar I Disorder

Otsuka and Lundbeck’s Abilify Asimtufii (aripiprazole) Receive the US FDA’s Approval as First Long-Acting Injectable for Schizophr...

  • April 27, 2023
PharmaShots Weekly Snapshots (December 18 – December 22, 2023)

    PharmaShots Weekly Snapshots (December 18 – December 22, 2023)

    • December 22, 2023
    Ionis and Otsuka Sign License Agreement to Develop and Commercialize Donidalorsen for Hereditary Angioedema (HAE) in Europe

      Ionis and Otsuka Sign License Agreement to Develop and Commercialize Donidalorsen for Hereditary Angioedema (HAE) in Europe

      • December 19, 2023
      PharmaShots Weekly Snapshots (November 06–10, 2023)

        PharmaShots Weekly Snapshots (November 06–10, 2023)

        • November 10, 2023
        The US FDA Approved Recor Medical and Otsuka Medical Devices’ Paradise Ultrasound Renal Denervation System for Hypertension

          The US FDA Approved Recor Medical and Otsuka Medical Devices’ Paradise Ultrasound Renal Denervation System for Hypertension

          • November 8, 2023
          PharmaShots Weekly Snapshots ( October 30– November 03, 2023)

            PharmaShots Weekly Snapshots ( October 30– November 03, 2023)

            • November 3, 2023
            Otsuka Pharmaceutical Reports Results from Two P-III Trials of Centanafadine to Treat ADHD

              Otsuka Pharmaceutical Reports Results from Two P-III Trials of Centanafadine to Treat ADHD

              • October 30, 2023
              Image

              Incisive News in 3 Shots.

              Contact Us

              Our Information

              Follow Us

              Copyright © 2025 PharmaShots - All Rights Reserved.